dostęp otwarty
Arypiprazol w dawce maksymalnej 30 mg i w połączeniu z olanzapiną
dostęp otwarty
Streszczenie
Streszczenie
Tytuł
Arypiprazol w dawce maksymalnej 30 mg i w połączeniu z olanzapiną
Czasopismo
Numer
Typ artykułu
Artykuł przeglądowy
Strony
71-75
Opublikowany online
2020-05-30
Wyświetlenia strony
1105
Wyświetlenia/pobrania artykułu
1048
DOI
Rekord bibliograficzny
Psychiatria 2020;17(2):71-75.
Autorzy
Paweł Mierzejewski
- Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010; 16(5): 488–501.
- Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs. 2004; 18(4): 251–267.
- Nagai T, Murai R, Matsui K, et al. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl). 2009; 202(1-3): 315–328.
- Di Sciascio G, Riva MA. Aripiprazole: from pharmacological profile to clinical use. Neuropsychiatr Dis Treat. 2015; 11: 2635–2647.
- Ribeiro EL, de Mendonça Lima T, Vieira ME, et al. Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews. Eur J Clin Pharmacol. 2018; 74(10): 1215–1233.
- Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013; 382(9896): 951–962.
- Sparshatt A, Taylor D, Patel MX, et al. A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010; 71(11): 1447–1456.
- Keck PE, Marcus R, Tourkodimitris S, et al. Aripiprazole Study Group. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003; 160(9): 1651–1658.
- Gerner RH, Post RM, Bunney WE. A dopaminergic mechanism in mania. Am J Psychiatry. 1976; 133(10): 1177–1180.
- Mamo D, Graff A, Mizrahi R, et al. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry. 2007; 164(9): 1411–1417.
- Natesan S, Reckless GE, Nobrega JN, et al. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology. 2006; 31(9): 1854–1863.
- Citrome L, Macher JP, Salazar DE, et al. Pharmacokinetics of aripiprazole and concomitant carbamazepine. J Clin Psychopharmacol. 2007; 27(3): 279–283.
- Belmonte C, Ochoa D, Román M, et al. Influence of CYP2D6, CYP3A4, CYP3A5 and ABCB1 Polymorphisms on Pharmacokinetics and Safety of Aripiprazole in Healthy Volunteers. Basic Clin Pharmacol Toxicol. 2018; 122(6): 596–605.
- Findling RL, Robb A, Nyilas M, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry. 2008; 165(11): 1432–1441.
- Byerly MJ, Marcus RN, Tran QV, et al. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res. 2009; 107(2-3): 218–222.
- Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry. 2008; 69(7): 1046–1056.
- Englisch S, Zink M. Combined antipsychotic treatment involving clozapine and aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008; 32(6): 1386–1392.
- Callaghan JT, Bergstrom RF, Ptak LR, et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999; 37(3): 177–193.
- Duggal HS. Aripirazole-olanzapine combination for treatment of schizophrenia. Can J Psychiatry. 2004; 49(2): 151.
- Choi YJ. Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis. ScientificWorldJournal. 2015; 2015: 970730.